Leerink Swann Reiterates a Buy Rating on Alexion Pharmaceuticals

By Ryan Adsit

In a report issued on November 4, Geoff Porges from Leerink Swann reiterated a Buy rating on Alexion Pharmaceuticals (NASDAQ: ALXN). The company’s shares opened today at $130.57.

According to TipRanks.com, Porges is ranked 0 out of 5 stars with an average return of -7.4% and a 13.6% success rate. Porges covers the Healthcare sector, focusing on stocks such as Theravance Biopharma, Johnson & Johnson, and Gilead Sciences.

Currently, the analyst consensus on Alexion Pharmaceuticals is Moderate Buy and the average price target is $173.33, representing a 32.7% upside.

In a report issued on October 27, Piper Jaffray also reiterated a Buy rating on the stock with a $176 price target.

Alexion Pharmaceuticals’ market cap is currently $28.92B and has a P/E ratio of 79.14. The company has a book value ratio of 3.5277.

Based on the recent corporate insider activity of 85 insiders, corporate insider sentiment is negative on the stock. Last month, Wagner Heidi L, the SVP, Global Government Affairs of ALXN sold 120 shares for a total of $14,689.

Alexion Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on serving patients with devastating and ultra-rare disorders through the innovation, development and commercialization of life-transforming therapeutic products. Its products include soliris, strensiq and kanuma. The company was founded by Joseph A. Madri, David W. Keiser, Stephen P. Squinto and Leonard Bell in January 1992 and is headquartered in New Haven, CT.